Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

Tag: evidence-review

  • What Does the Published Research Say About Dilute Acetic Acid as a Laboratory Reagent?

    Research Context

    The packet is heterogeneous. It includes: (a) one human clinical study in hemodialysis patients evaluating propolis (not a reagent study) [pubmed:39453192]; (b) a clinical nutrition meta-analysis on vinegar ingestion and metabolic endpoints [pubmed:28292654]; (c) domain reviews not focused on laboratory reagent performance [pubmed:30074030; pubmed:16202844; pubmed:36985356]; (d) preclinical/methods/informatics papers that do not directly assess dilute acetic acid as a peptide-focused reagent [pubmed:31472480; pubmed:38117889; pubmed:38359688]; (e) engineering/processing items involving dilute acetic acid outside peptide/proteomics scope [crossref:10.1021/acssuschemeng.1c02937.s001; crossref:10.58837/chula.the.2006.1639]; and (f) standards/monographs for acetic acid grades [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].

    Key Takeaway

    Within this packet, no primary bench studies evaluate dilute acetic acid performance in peptide or proteomics workflows. Standards list grades; clinical, review, preclinical, methods, and engineering items are contextual only and should not be extrapolated to reagent efficacy.

    Direct Answer

    • Within this packet, there are no primary bench studies that directly evaluate dilute acetic acid as a laboratory reagent for peptide solubilization, sample preparation, LC–MS performance, or related workflow metrics [pubmed:31472480; pubmed:38117889; pubmed:38359688].
    • Standards/monographs specify acetic acid grades (e.g., glacial, dilute, ultratrace) but, within this packet, they do not validate performance for peptide/proteomics workflows [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].
    • Human clinical literature included here (propolis in hemodialysis; vinegar ingestion meta-analysis) addresses unrelated endpoints and should not be extrapolated to laboratory reagent performance [pubmed:39453192; pubmed:28292654].

    Human Evidence (Clinical)

    • A clinical study of propolis in patients undergoing hemodialysis reports effects on gut microbiota and uremic toxin profiles [pubmed:39453192]. This is unrelated to dilute acetic acid and does not evaluate laboratory reagent performance.

    Review and Translational Context (Not Primary Evidence)

    • A systematic review/meta-analysis on vinegar ingestion and postprandial glucose/insulin responses examines dietary exposure and metabolic endpoints, not laboratory reagent performance [pubmed:28292654].
    • Additional domain reviews (e.g., polyketide synthase–NRPS interactions; cerumen removal products; phosphate-solubilizing bacteria) are tangential and should not be interpreted as evidence for dilute acetic acid as a peptide/proteomics reagent [pubmed:30074030; pubmed:16202844; pubmed:36985356].
    • Other screened literature (e.g., tryptophan metabolites and Aβ; silicate- or phosphate-solubilizing bacteria; peptide 14C-labeling) provides mechanistic or domain-specific context only, not reagent performance data [pubmed:32360535; pubmed:34225007; pubmed:36494624; pubmed:3379315].

    Preclinical, Methods, Engineering, and Standards (Context Only)

    • Methods/informatics papers in the packet do not establish dilute acetic acid usage or quantify concentration–performance relationships for peptide workflows:
    • Microwave-assisted acid hydrolysis for whole-bone proteomics/paleoproteomics is a sample-prep method paper and does not evaluate dilute acetic acid for peptide solubilization performance [pubmed:31472480].
    • Cobalt-catalyzed umpolung hydrogenation for unnatural peptide synthesis is synthetic methodology unrelated to acetic acid as a solubilizing reagent or sample-prep additive [pubmed:38117889].
    • LC–MS retention-time prediction for phosphorylated peptides is computational/informatics work and does not test dilute acetic acid as a mobile-phase additive or assess concentration–performance tradeoffs [pubmed:38359688].
    • Engineering/processing items are out of scope for peptide/proteomics reagent performance:
    • Dilute acetic acid hydrolysis for xylooligosaccharide production in biomass processing does not assess peptide workflows [crossref:10.1021/acssuschemeng.1c02937.s001].
    • Reactive distillation using dilute acetic acid to produce n-butyl acetate is a process engineering study, not a reagent performance evaluation for peptides [crossref:10.58837/chula.the.2006.1639].
    • Standards/monographs specify properties and grades (e.g., glacial vs dilute; ultratrace) but, within this packet, are not empirical demonstrations of performance in peptide or proteomics workflows [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401]. Patent listings are non-evidentiary for performance claims [patent_search:dilute-acetic-acid-peptide-solubilization-laboratory-reagent].

    What Is Not Established Within This Packet

    • Direct bench evidence validating dilute acetic acid for peptide recovery, compatibility, LC–MS performance, or other workflow metrics in proteomics or related laboratory applications is not present [pubmed:31472480; pubmed:38117889; pubmed:38359688].
    • While standards/monographs may include limited procedural notes, they do not provide protocol-level guidance or comparative performance validation for laboratory use here [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].
    • Dosing, concentration, safety parameters, and standard-of-use protocols for dilute acetic acid in laboratory workflows are not established by the materials in this packet [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].

    Notes for Researchers

    • If considering dilute acetic acid for a workflow, design bench-level comparisons versus relevant alternatives across sample types and downstream assays (e.g., recovery, analyte stability, matrix effects, interference, reproducibility). Until such data exist, keep human clinical and review context separate from reagent performance claims.

    FAQ

    • Does this packet contain bench evidence that dilute acetic acid improves peptide solubilization or LC–MS performance?
    • No. Within this packet, there are no primary bench studies directly testing dilute acetic acid performance in peptide/proteomics workflows [pubmed:31472480; pubmed:38117889; pubmed:38359688].
    • Can the acetic acid standards/monographs here be used to infer protocol concentrations or efficacy in peptide workflows?
    • Not from this packet. They specify grades and properties, but do not validate concentration–performance relationships for peptide applications [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].
    • Are any included human clinical data relevant to using dilute acetic acid as a lab reagent?
    • No. The clinical items address propolis in hemodialysis patients and vinegar ingestion effects on metabolism—neither evaluates laboratory reagent performance [pubmed:39453192; pubmed:28292654].
    • Do the engineering papers on biomass hydrolysis or reactive distillation inform peptide reagent use?
    • No. They address process engineering contexts and do not test peptide or proteomics workflows [crossref:10.1021/acssuschemeng.1c02937.s001; crossref:10.58837/chula.the.2006.1639].
    • Should methods or informatics papers in this packet be treated as efficacy evidence for dilute acetic acid in proteomics?
    • No. These are context-only and do not establish reagent efficacy [pubmed:31472480; pubmed:38117889; pubmed:38359688].

    References

    • Clinical / human: [pubmed:39453192] https://pubmed.ncbi.nlm.nih.gov/39453192/
    • Reviews / context: [pubmed:28292654] https://pubmed.ncbi.nlm.nih.gov/28292654/; [pubmed:30074030] https://pubmed.ncbi.nlm.nih.gov/30074030/; [pubmed:16202844] https://pubmed.ncbi.nlm.nih.gov/16202844/; [pubmed:36985356] https://pubmed.ncbi.nlm.nih.gov/36985356/
    • Preclinical / methods / informatics: [pubmed:31472480] https://pubmed.ncbi.nlm.nih.gov/31472480/; [pubmed:38117889] https://pubmed.ncbi.nlm.nih.gov/38117889/; [pubmed:38359688] https://pubmed.ncbi.nlm.nih.gov/38359688/
    • Engineering / processing: [crossref:10.1021/acssuschemeng.1c02937.s001] https://doi.org/10.1021/acssuschemeng.1c02937.s001; [crossref:10.58837/chula.the.2006.1639] https://doi.org/10.58837/chula.the.2006.1639
    • Standards / monographs: [crossref:10.3403/30305818] https://doi.org/10.3403/30305818; [crossref:10.1021/acsreagents.4003.20160601] https://doi.org/10.1021/acsreagents.4003.20160601; [crossref:10.1021/acsreagents.4003.20250401] https://doi.org/10.1021/acsreagents.4003.20250401
    • Additional screened (unrelated to reagent performance): [pubmed:32360535] https://pubmed.ncbi.nlm.nih.gov/32360535/; [pubmed:34225007] https://pubmed.ncbi.nlm.nih.gov/34225007/; [pubmed:36494624] https://pubmed.ncbi.nlm.nih.gov/36494624/; [pubmed:3379315] https://pubmed.ncbi.nlm.nih.gov/3379315/
    • Patent listings (non-evidentiary): [patent_search:dilute-acetic-acid-peptide-solubilization-laboratory-reagent] https://patents.google.com/?q=dilute+acetic+acid+peptide+solubilization+laboratory+reagent

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Semaglutide?

    Research Context

    The synthesis packet contains 12 PubMed-indexed sources: eight primary human studies and four reviews; no preclinical sources. Conclusions should remain anchored to the specific populations, endpoints, and formulations explicitly studied. Review literature can frame context but does not substitute for primary human outcome data.

    Direct Answer

    Published human randomized trials in this packet most robustly report weight-management outcomes primarily in adults with overweight or obesity without diabetes, using both subcutaneous and oral formulations [pubmed:35015037][pubmed:37385278][pubmed:38330988]. Additional human research addresses functional capacity (walking outcomes) in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145]. Cardiovascular outcomes and metabolic dysfunction–associated steatohepatitis (MASH) are represented here only by trial design/baseline publications, without reported outcomes [pubmed:36945734][pubmed:39412509]. Systematic reviews synthesize efficacy in obesity without diabetes; a safety-focused review addresses semaglutide more broadly and should not be over-narrowed to obesity-only contexts [pubmed:36578889][pubmed:38679221][pubmed:34942372][pubmed:34305810].

    Human Clinical Evidence

    • Weight management in adults (primarily without diabetes)
    • STEP 8: Weekly subcutaneous semaglutide versus daily liraglutide; primary outcomes centered on body-weight change in adults with overweight or obesity without diabetes [pubmed:35015037].
    • OASIS 1: Oral semaglutide 50 mg once daily versus placebo; weight outcomes in adults with overweight or obesity (the title does not specify diabetes status) [pubmed:37385278].
    • STEP 7: Once-weekly semaglutide 2.4 mg versus placebo; weight outcomes in a predominantly East Asian population with overweight or obesity [pubmed:38330988].
    • Functional capacity in peripheral artery disease with type 2 diabetes
    • STRIDE (phase 3b): Double-blind, randomized, placebo-controlled trial evaluating walking capacity endpoints in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145].
    • Cardiovascular outcomes (design/baseline only in this packet)
    • SOUL: Design and baseline characteristics for a randomized cardiovascular outcomes trial of oral semaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease; no outcomes are reported in the materials provided here [pubmed:36945734].
    • MASH (design/baseline only in this packet)
    • ESSENCE (phase 3): Baseline characteristics and trial design evaluating semaglutide 2.4 mg in participants with MASH; no outcomes are reported in the materials provided here [pubmed:39412509].
    • Comparator and combination contexts (do not imply monotherapy outcomes)
    • Tirzepatide comparator trial (phase 1): Multicenter, randomized, double-blind study comparing tirzepatide with placebo or semaglutide on islet function and insulin sensitivity in adults with type 2 diabetes; this context does not establish semaglutide monotherapy efficacy beyond its role as a comparator [pubmed:35468322].
    • Cagrilintide–semaglutide combination: Study in adults with overweight or obesity and type 2 diabetes; as a combination therapy, it does not isolate semaglutide monotherapy effects [pubmed:40544432].

    Outcome evidence is strongest for weight-management trials primarily in adults without diabetes. Cardiovascular and MASH questions are represented here by design/baseline papers only and should not be interpreted as established clinical outcomes within this packet.

    Review Literature

    • Systematic review and meta-analysis on efficacy and safety for weight loss in obesity without diabetes [pubmed:36578889].
    • Systematic review and meta-analysis on long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes across randomized controlled trials [pubmed:38679221].
    • Review on semaglutide for the treatment of obesity [pubmed:34942372].
    • Safety-focused review addressing semaglutide broadly (not limited to obesity without diabetes) [pubmed:34305810].

    These reviews contextualize mechanisms, efficacy, and safety but remain limited by the included primary RCTs and do not extend findings to unstudied populations, endpoints, or formulations beyond those tested.

    Preclinical and Mechanistic Evidence

    • No preclinical or purely mechanistic sources are included in the packet.

    What Is Not Established

    • Cardiovascular outcomes and MASH efficacy: Only trial designs/baseline characteristics are included (SOUL, ESSENCE); no outcome data are provided here and efficacy should not be inferred.
    • Generalized dosing and safety extrapolation beyond the studied contexts.
    • Anti-aging or broad peptide claims unsupported by direct human outcomes in this packet.
    • Cross-formulation or cross-population generalizations not tested in the cited studies.

    References

    • [pubmed:35015037] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/35015037/
    • [pubmed:37385278] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/37385278/
    • [pubmed:38330988] Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. https://pubmed.ncbi.nlm.nih.gov/38330988/
    • [pubmed:40169145] Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/40169145/
    • [pubmed:36945734] Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. https://pubmed.ncbi.nlm.nih.gov/36945734/
    • [pubmed:39412509] Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. https://pubmed.ncbi.nlm.nih.gov/39412509/
    • [pubmed:35468322] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. https://pubmed.ncbi.nlm.nih.gov/35468322/
    • [pubmed:40544432] Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/40544432/
    • [pubmed:36578889] Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/36578889/
    • [pubmed:38679221] Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://pubmed.ncbi.nlm.nih.gov/38679221/
    • [pubmed:34942372] Semaglutide for the treatment of obesity. https://pubmed.ncbi.nlm.nih.gov/34942372/
    • [pubmed:34305810] Safety of Semaglutide. https://pubmed.ncbi.nlm.nih.gov/34305810/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About DSIP?

    Research Context

    Delta sleep-inducing peptide (DSIP) has been investigated for decades, but the literature base is weighted toward reviews and preclinical studies rather than controlled human interventions. Multiple DSIP-focused reviews from the 1980s and mid-2000s describe uncertainty around mechanism and clinical role, with one calling DSIP “a still unresolved riddle” [pubmed:6145137; pubmed:3550726; pubmed:16539679; pubmed:11437870]. DSIP is also discussed within broader overviews of endogenous sleep substances [pubmed:3541663]. General peptide surveys sometimes mention DSIP in passing [pubmed:41490200], but they do not supply DSIP-specific human efficacy evidence. Overall, the packet’s citations are heterogeneous and include older reviews, with limited human observational data and several model-specific animal studies.

    Direct Answer

    Published DSIP research is dominated by reviews and animal models. The packet identifies one human observational study measuring DSIP-like immunoreactivity (DSIP-LI) in relation to delta sleep in schizophrenic volunteers; this was not an interventional administration study and does not demonstrate clinical benefit [pubmed:1475566]. No controlled interventional human trials are shown in the packet. Consequently, dosing parameters, safety in humans, and broad clinical efficacy claims are not established by this evidence base [pubmed:11437870; pubmed:6145137; pubmed:16539679; pubmed:3550726].

    Human Evidence (Observational)

    • DSIP-like immunoreactivity and delta sleep in schizophrenic volunteers: This study assessed biomarker/immunoreactivity associations with sleep physiology in a specific population; it did not administer DSIP and does not establish therapeutic efficacy or generalizable clinical outcomes [pubmed:1475566].

    The strongest conclusions should remain limited to the specific population, endpoint, and observational nature of this finding, consistent with DSIP-focused reviews that emphasize the narrow and uncertain human evidence base [pubmed:11437870; pubmed:6145137; pubmed:16539679; pubmed:3550726].

    Review Literature on DSIP

    • Historical and update reviews consolidated early observations but did not resolve mechanism or clinical role [pubmed:6145137; pubmed:3550726].
    • A later assessment characterized DSIP as an unresolved problem in terms of mechanism and human relevance [pubmed:16539679].
    • A broader overview places DSIP among endogenous sleep substances without establishing clinical utility [pubmed:3541663].
    • DSIP-focused summaries collectively support a cautious view: human evidence remains narrow and context-specific, and extrapolation is unwarranted [pubmed:11437870; pubmed:6145137; pubmed:16539679; pubmed:3550726].
    • General peptide surveys (e.g., orthopaedics-focused) may list DSIP but should not be interpreted as DSIP-specific human efficacy support [pubmed:41490200].

    Preclinical and Mechanistic Evidence

    • Rodent seizure model: DSIP was evaluated for effects on incidence and severity in a metaphit-induced epilepsy rat model, providing model-specific findings that do not establish human efficacy [pubmed:11884222].
    • Mechanistic/circadian hypotheses: Suggested links between DSIP, glucocorticoid-induced leucine zipper (GILZ), and circadian processes have been proposed, including speculative connections to obesity pathways; these remain hypotheses without demonstrated clinical translation [pubmed:19849801].
    • Mouse insomnia model and BBB: DSIP fusion peptides secreted by Pichia pastoris were reported to cross the blood–brain barrier and show “efficacy” within a para-chlorophenylalanine (PCPA)-induced insomnia mouse model. These observations are confined to that specific model and experimental construct and do not establish BBB transport or therapeutic efficacy in humans [pubmed:39444618].

    What Is Not Established (Key Gaps)

    • No controlled interventional human trials are shown in the packet [pubmed:11437870; pubmed:6145137; pubmed:16539679; pubmed:3550726].
    • Human dosing parameters and safety profile are not established by the cited literature.
    • Reproducible human clinical outcomes and standardized endpoints are not demonstrated.
    • Anti-aging or broad clinical-utility claims are unsupported by this evidence base.
    • Mechanistic plausibility and animal-model findings should not be converted into presumed human efficacy.
    • Model-specific BBB and behavioral effects in mice do not generalize to humans.

    Overall, the current DSIP literature provides hypotheses and model data but does not substantiate generalized human efficacy or safety claims.

    References

    • [pubmed:11437870] Delta sleep-inducing peptide. https://pubmed.ncbi.nlm.nih.gov/11437870/
    • [pubmed:41490200] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://pubmed.ncbi.nlm.nih.gov/41490200/
    • [pubmed:6145137] Delta-sleep-inducing peptide (DSIP): a review. https://pubmed.ncbi.nlm.nih.gov/6145137/
    • [pubmed:16539679] Delta sleep-inducing peptide (DSIP): a still unresolved riddle. https://pubmed.ncbi.nlm.nih.gov/16539679/
    • [pubmed:3550726] Delta-sleep-inducing peptide (DSIP): an update. https://pubmed.ncbi.nlm.nih.gov/3550726/
    • [pubmed:3541663] Sleep and sleep substances. https://pubmed.ncbi.nlm.nih.gov/3541663/
    • [pubmed:11884222] The effects of delta sleep-inducing peptide on incidence and severity in metaphit-induced epilepsy in rats. https://pubmed.ncbi.nlm.nih.gov/11884222/
    • [pubmed:19849801] Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity? https://pubmed.ncbi.nlm.nih.gov/19849801/
    • [pubmed:1475566] Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers. https://pubmed.ncbi.nlm.nih.gov/1475566/
    • [pubmed:39444618] Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. https://pubmed.ncbi.nlm.nih.gov/39444618/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides